HIV
HIV-1 is an RNA retrovirus that infects immune cells through the envelope glycoprotein Env, whose mature gp120/gp41 trimer mediates viral entry into host cells[1]. Mechanistically, gp120 binds CD4 and then the chemokine coreceptors CCR5 or CXCR4, while gp41 refolding brings viral and cellular membranes together for fusion[2][3]. After entry, viral replication depends on reverse transcriptase, protease, and integrase, making these enzymes core targets for antiretroviral research[4][5]. In disease relevance, untreated HIV replication causes progressive CD4+ T-cell loss and immunological abnormalities, increasing infectious and oncological complications[6]. Compared with related forms, HIV-1 remains the main focus because it is described as the most virulent and pathogenic subtype in diagnostic and treatment literature[7]. For experimental applications, entry inhibitors target gp120, gp41, CCR5, or CXCR4, while enzyme inhibitors target reverse transcriptase, protease, or integrase to suppress distinct stages of the HIV life cycle[4][8].
References:
- [1]. Anang S, et al. Characterization of full-length and cytoplasmic tail-truncated envelope glycoproteins incorporated into human immunodeficiency virus (HIV-1) virions and virus-like particles. J Virol. 2025 Dec 23;99(12):e0158525. [Content Brief]
- [2]. Teixeira C, et al. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur J Med Chem. 2011 Apr;46(4):979-92. [Content Brief]
- [3]. Princen K, et al. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. [Content Brief]
- [4]. De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. doi: 10.1517/14728214.10.2.241. PMID: 15934866. et al. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. [Content Brief]
- [5]. Palmisano L. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. doi: 10.1586/14787210.5.1.67. PMID: 17266455. et al. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75. [Content Brief]
- [6]. Deeks SG, et al. HIV infection. Nat Rev Dis Primers. 2015 Oct 1;1:15035. [Content Brief]
- [7]. Zulfiqar HF, et al. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health. 2017 Mar 7;5:32. [Content Brief]
- [8]. Greenberg M, et al. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol. 2004 Sep-Oct;14(5):321-37. [Content Brief]
All Product Categories
-
HIV Related Products (903)
Related Products (903)
-
Stachybotrylactam
0 ImagesCat. No.: HY-124477CAS No.: 163391-76-2Stachybotrylactam (17) is a phenylspirodrimane isolated from Stachybotrys chartarum with antihyperlipidemic activity. Stachybotrylactam also has antiviral activity.
-
Curromycin A
0 ImagesCat. No.: HY-N14095CAS No.: 97412-76-5Curromycin A has antibacterial activity against Gram-positive bacteria such as Bacillus subtilis. Curromycin A can inhibit the replication of human immunodeficiency virus (HIV), inhibit mouse melanoma B16 and leukemia P388 cells.
-
Raltegravir-d4 potassium
0 ImagesCat. No.: HY-10353AS2Synonyms: MK 0518-d4 potassiumRaltegravir-d4 (potassium) (MK 0518-d4 (potassium)) is deuterium labeled Raltegravir (potassium). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
-
TSAO-T
0 ImagesCat. No.: HY-15354CAS No.: 141781-17-1TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection.
-
DPC 961
0 ImagesCat. No.: HY-107001CAS No.: 214287-88-4Synonyms: (S)-DPC 961; DMP 961DPC 961 (DMP 961) is a non-nucleoside reverse transcriptase inhibitor (NNRTI). DPC 961 is a potent and specific inhibitor of HIV-1 reverse transcriptase, which inhibits the activity of HIV-1 reverse transcriptase in a non-competitive manner, thereby preventing viral replication. DPC 961 can be used for research on AIDS.
-
PROTAC HIV-1 degrader-1
0 ImagesCat. No.: HY-187361CAS No.: 3107740-33-7PROTAC HIV-1 degrader-1 is a HIV-1 capsid (CA) PROTAC degrader, with a DC50 of 3 nM against HIV-1IIIB (MT‑4 cells) and a DC50 of 1.17 nM against HIV-1NL4-3 (MT‑4 cells). PROTAC HIV-1 degrader-1 conjugates HIV-1 capsid (CA) with the VHL E3 ubiquitin ligase, triggering polyubiquitination and proteasome-mediated degradation of CA, as well as competitively inhibiting the binding of host factors CPSF6 and Sec24C to CA. PROTAC HIV-1 degrader-1 degrades CA drug-resistant mutants (N74D, K70R). PROTAC HIV-1 degrader-1 is applicable to research related to HIV-1 infection.
-
3′-Azido-2′,3′-dideoxy-CTP
0 ImagesCat. No.: HY-171574CAS No.: 92562-77-1Synonyms: AZddCTP3′-Azido-2′,3′-dideoxy-CTP (AZddCTP) is a cytidine analog containing a 3-azido group. As a chain terminator, 3′-Azido-2′,3′-dideoxy-CTP can be incorporated into the nascent DNA chain by HIV reverse transcriptase. 3′-Azido-2′,3′-dideoxy-CTP terminates DNA synthesis due to the lack of a 3'-hydroxyl group, thereby inhibiting viral replication. 3′-Azido-2′,3′-dideoxy-CTP has IC50 values of 15.6 μM and 160.8 μM for WT HIV and AZTR HIV. 3′-Azido-2′,3′-dideoxy-CTP has antiviral activity.
-
Elsulfavirine (Standard)
0 ImagesCat. No.: HY-109056RCAS No.: 868046-19-9Synonyms: R-1206 (Standard)Elsulfavirine (Standard) is the analytical standard of Elsulfavirine (HY-109056). This product is intended for research and analytical applications. Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer.
-
Vif-ElonginC interaction inhibitor 1
0 ImagesCat. No.: HY-120157CAS No.: 374679-27-3Vif-ElonginC interaction inhibitor 1 (compound VEC-5) is a potent Vif inhibitor. Vif-ElonginC interaction inhibitor 1 can restrict HIV-1 in Vif-nonpermissive cells. Vif-ElonginC interaction inhibitor 1 can protect A3G, APOBEC3C (A3C), and APOBEC3F (A3F) from Vif-mediated degradation and drastically inhibit Vif function through blocking the interaction between Vif and ElonginC. Vif-ElonginC interaction inhibitor 1 enhances A3G incorporation into HIV-1 virions to reduce viral infectivity.
-
DPC 963
0 ImagesCat. No.: HY-117477CAS No.: 214287-90-8DPC-963 is an oral active non-nucleoside reverse transcriptase inhibitor with the IC50 of 18 nM. DPC-963 can be used for study of HIV.
-
NNRT-IN-6
0 ImagesCat. No.: HY-172408NNRT-IN-6 (Compound 13a) is the non-nucleoside reverse transcriptase inhibitor (NNRT) for HIV-1 reverse transcriptase (HIV-1 RT) with IC50 of 0.41 μM. NNRT-IN-6 inhibits HIV-1 wildtype and mutant strains L100I, K103N, Y181C, Y188L, E138K, F227L/V106A and RES056 with EC50 of 6.2-250 nM.
-
019854-B06
0 ImagesCat. No.: HY-180187019854-B06 is a potent inhibitor of Tat-mediated HIV-1 transcription (IC50 = 1.44 μM), exhibiting antiviral activity against HIV-1 (EC50 = 0.83 μM). 019854-B06 binds to Tat peptide (KD = 33.5 μM), but not to TAR RNA. 019854-B06 neither promotes Tat degradation nor disrupts the Tat/CycT1 complex, supporting a Tat-centric, nondegradative mechanism.
-
Fostemsavir-d8
0 ImagesCat. No.: HY-15440ASSynonyms: BMS-663068-d8
-
Calceolarioside A
0 ImagesCat. No.: HY-123896CAS No.: 84744-28-5Calceolarioside A is phenylethanoid glycoside with moderate binding affinity on HIV gp41.
-
GS-9148
0 ImagesCat. No.: HY-122018CAS No.: 875608-25-6GS-9148 is a ribose-modified HIV-1 nucleotide reverse transcriptase (RT) inhibitor with an EC50 value of 10.6 µM. GS-9148 shows antiretroviral activity for K65R, L74V, or M184V RT mutation.
-
BMS-663749
0 ImagesCat. No.: HY-120630CAS No.: 864953-33-3
-
Ebselen (Standard)
0 ImagesCat. No.: HY-13750RCAS No.: 60940-34-3Synonyms: SPI-1005 (Standard); PZ-51 (Standard); CCG-39161 (Standard)Ebselen (Standard) is the analytical standard of Ebselen (HY-13750). This product is intended for research and analytical applications. Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent voltage-dependent calcium channel (VDCC) blocker. Ebselen potently inhibits Mpro (IC50=0.67 μM) and COVID-19 virus (EC50=4.67 μM).Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen, an organoselenium compound, can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity.
-
A-75925
0 ImagesCat. No.: HY-125433CAS No.: 129467-48-7
-
U 89674
0 ImagesCat. No.: HY-187598CAS No.: 144674-89-5U 89674 is a nonnucleoside HIV-1 reverse transcriptase inhibitor with no cytotoxic effect on cells at concentrations of 10 μM or lower over 7 days. U 89674 modulates reverse transcriptase activity, interfering with HIV-1 replication. U 89674 inhibits replication of HIV-1 laboratory strains and primary HIV-1 isolates in immune cells. U 89674 delays virus-induced cell killing in mixed cultures of uninfected and HIV-1-infected cells. U 89674 can be used for the research of HIV-1 infection.
-
ITI-367
0 ImagesCat. No.: HY-182566CAS No.: 288246-59-3ITI-367 is a HIV-1 inhibitor that targets the nuclear localization signal 1 (NLS-1) of HIV-1 matrix protein and the interaction between HIV-1 pre-integration complex (PIC) and importin-β. ITI-367 inhibits HIV-1 replication at the pre-integration stage, reduces the formation of 2-LTR circles, and sequesters viral DNA in the cytoplasm. ITI-367 can be used for the research of HIV infection.
